Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fl

Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidine is a phase 1/2, interventional study registered as NCT07683949 by Seoul National University Bundang Hospital, with a registry enrolment figure of 93 participants, started 2026-06-15 and due to reach its primary completion in 2029-10-31. Interventions recorded: Lenvanib (Lenvatinib),Xeloda (capecitabine). Conditions listed: Advanced Colorectal Cancer (Part 1). Primary outcome: Primary Efficacy Analysis. Colorectal eligibility wording from the registry: "* 1\) Voluntarily signed written informed consent 2) Male or female ≥19 years of age 3) Histologically confirmed metastatic or unresectable colorectal adenocarcinoma 4) Metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines 5) ECOG performance status 0, 1, or 2 6) ". Sites: South Korea. No results are recorded here; the registry entry is the source.